NA
FULC icon

NewEdge Advisors’s Fulcrum Therapeutics FULC Stock Holding History

NewEdge Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$12 – 3952
2024
Q3 		$12 Buy
+3
New +$22 ﹤0.01% 3782

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

NewEdge Advisors's FULC Position: Q4 2024 in Review

NewEdge Advisors sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 3 shares — an estimated $12 sold.

NewEdge Advisors first reported a position in FULC in Q3 2024 and held it in 1 quarter. The position peaked at $12 in Q3 2024. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • NewEdge Advisors reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • NewEdge Advisors sold 3 Fulcrum Therapeutics shares in Q4 2024, an estimated $12.
  • NewEdge Advisors first reported a position in Fulcrum Therapeutics in Q3 2024 and held it in 1 quarter.
  • NewEdge Advisors's Fulcrum Therapeutics position peaked at $12 in Q3 2024.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on NewEdge Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.